Target Reprogramming Lysosomes of CD8+ T Cells by a Mineralized Metal–Organic Framework for Cancer Immunotherapy

Qin Zhao,Zijian Gong,Zhihao Li,Jinyang Wang,Jinglun Zhang,Zifan Zhao,Peng Zhang,Shihang Zheng,Richard J. Miron,Quan Yuan,Yufeng Zhang

DOI: https://doi.org/10.1002/adma.202100616

IF: 29.4

2021-03-24

Advanced Materials

Abstract:T cell immunotherapy holds significant challenges in solid tumors, mainly due to the T cells' low activation and the decreased synthesis-release of therapeutic proteins, including perforin and granzyme B, which are present in lysosomes. In this study, a lysosome-targeting nanoparticle (LYS-NP) is developed by way of a mineralized metal-organic framework (MOF) coupled with a lysosome-targeting aptamer (CD63-aptamer) to enhance the antitumor effect of T cells. The MOF synthesized from Zn²⁺ and dimethylimidazole has good protein encapsulation and acid sensitivity, and is thus an ideal lysosomal delivery vector. Calcium carbonate (CaCO₃ ) is used to induce MOF mineralization, improve the composite material's stability in encapsulating therapeutic protein, and provide calcium ions with synergistic effects. Before mineralization, perforin and granzyme B-T cell-needed therapeutic proteins for tumors-are preloaded with the MOF. Moreover, T cells are pretreated with processed tumor-specific antigens to activate or produce memory before reprogramming the lysosomes, facilitating the T cell receptor (TCR) for release of the therapeutic proteins. Using T cells recombined by LYS-NPs, a significant enhancement of breast cancer control is confirmed.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper aims to address a critical issue in solid tumor immunotherapy, namely how to enhance the activation of T cells within solid tumors and improve their ability to synthesize and release anti-tumor proteins such as perforin and granzyme B. Specifically, the research team developed a lysosome-targeting nanoparticle (LYS-NP) by combining a mineralized metal-organic framework (MOF) with a lysosome-targeting aptamer (CD63-aptamer) to enhance the anti-tumor effects of CD8+ T cells. This strategy aims to overcome the challenges faced by current adoptive T cell therapies in treating solid tumors, such as insufficient T cell activation and reduced secretion of anti-tumor proteins. By using this novel nanoparticle, the study demonstrated that the reprogrammed T cells could significantly improve breast cancer control.